• OPEN AN ACCOUNT
Indian Indices
Sensex
83,382.71 -244.98
( -0.29%)
Global Indices
Nasdaq
49,156.99 -56.01
(-0.11%)
Dow Jones
6,945.95 -38.79
(-0.56%)
Hang Seng
53,810.56 -530.67
(-0.98%)
Nikkei 225
10,167.22 29.87
(0.29%)
Forex
USD-INR
90.25 0.03
(0.03%)
EUR-INR
105.19 0.24
(0.23%)
GBP-INR
121.43 0.56
(0.46%)
JPY-INR
0.57 0.00
(-0.55%)

EQUITY - MARKET SCREENER

Jay Shree Tea & Industries Ltd
Industry :  Tea
BSE Code
ISIN Demat
Book Value()
509715
INE364A01020
142.098338
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
JAYSREETEA
11.26
247.13
EPS(TTM)
Face Value()
Div & Yield %
7.6
5
0.58
 

Gland Pharma climbs on USFDA nod for allergy eye drug
Jan 08,2026
The said drug is therapeutically equivalent to the reference listed drug (RLD), Pataday Once Daily Relief, 0.7%, of Alcon Laboratories Inc (Alcon). The said drug indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

The company’s consolidated net profit increased 12.3% to Rs 183.68 crore on 5.8% rise in net sales to Rs 1486.88 crore in Q2 FY26 over Q2 FY25.